

Maria Varela Calvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9234661/publications.pdf>

Version: 2024-02-01

89
papers

5,102
citations

411340

20
h-index

107981

68
g-index

106
all docs

106
docs citations

106
times ranked

6367
citing authors

#	ARTICLE	IF	CITATIONS
1	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. Journal of Clinical Oncology, 2022, 40, 428-428.	0.8	6
2	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	1.9	11
3	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
4	Low applicability of the six-and-twelve score in hepatocellular carcinoma treated with drug-eluting beads transarterial chemoembolization. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.1	2
5	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	1.2	20
6	Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation. Digestive and Liver Disease, 2021, 53, S11.	0.4	1
7	Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver International, 2021, 41, 2200-2211.	1.9	8
8	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina Clínica (English Edition), 2021, 156, 463.e1-463.e30.	0.1	16
9	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
10	Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis. American Journal of Gastroenterology, 2021, 116, 2390-2398.	0.2	19
11	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
12	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers, 2020, 12, 1900.	1.7	14
13	The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization. BMC Gastroenterology, 2020, 20, 166.	0.8	5
14	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	1.9	15
15	Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus. Revista Espanola De Enfermedades Digestivas, 2020, 112, 538-544.	0.1	0
16	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	2.6	60
17	SAT-129-Type 2 diabetes in patients with liver cirrhosis: prevalence, associated factors and influence on survival. Journal of Hepatology, 2019, 70, e687.	1.8	0
18	SAT-460-Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis. Journal of Hepatology, 2019, 70, e835.	1.8	0

#	ARTICLE	IF	CITATIONS
19	SAT-489-Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma and high comorbidity. <i>Journal of Hepatology</i> , 2019, 70, e848-e849.	1.8	0
20	FRI-022-Characteristics of autoimmune hepatitis with acute presentation. <i>Journal of Hepatology</i> , 2019, 70, e393.	1.8	0
21	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	1.8	67
22	FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study. <i>Journal of Hepatology</i> , 2019, 70, e606-e607.	1.8	0
23	Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study. <i>Digestive and Liver Disease</i> , 2019, 51, e12.	0.4	1
24	Incidence and risk factors associated with hepatocellular carcinoma surveillance failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1524-1529.	1.4	18
25	Oral oxycodone/naloxone for pain control in cirrhosis: Start slow, go slow. <i>Liver International</i> , 2018, 38, 227-228.	1.9	0
26	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	3.6	55
27	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , 2018, 9, 30869-30882.	0.8	9
28	Hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA) does not show differences at diagnosis compared with HCC after IFN-based treatments. Results of a national HCC Registry in Spain. <i>Journal of Hepatology</i> , 2018, 68, S418-S419.	1.8	0
29	Factors implicated in the risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis due to HCV Implications of Sustained Virological Response (SVR). <i>Journal of Hepatology</i> , 2018, 68, S431-S432.	1.8	0
30	Usefulness of liver stiffness measurement by transient elastography for predicting complications in patients with alcoholic liver disease. <i>Journal of Hepatology</i> , 2018, 68, S638.	1.8	1
31	Efficacy and safety of REGORAFENIB in real life in the treatment of hepatocellular carcinoma. Multicenter experience. <i>Journal of Hepatology</i> , 2018, 68, S15.	1.8	1
32	Analysis of the influence of alcohol abstinence on the risk of developing hepatocellular carcinoma (HCC) in patients with alcoholic liver cirrhosis (ALC). <i>Journal of Hepatology</i> , 2018, 68, S35.	1.8	0
33	Changes in the characteristics of hospital admissions due to complications of cirrhosis in the era of direct-acting antivirals against HCV. <i>Journal of Hepatology</i> , 2018, 68, S305-S306.	1.8	0
34	Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth. <i>Journal of Hepatology</i> , 2017, 66, S20.	1.8	10
35	Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 66, S209.	1.8	0
36	Alpha-fetoprotein levels before and after sustained virological response with direct-acting antivirals in patients with liver cirrhosis due to hepatitis C virus. <i>Journal of Hepatology</i> , 2017, 66, S216.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Transient elastography evolution in non treated patients with chronic hepatitis B (CHB) infection. Journal of Hepatology, 2017, 66, S254.	1.8	0
38	Temporary suspension of sorafenib by adverse effects is associated with longer survival in patients with hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S448.	1.8	0
39	Previous and resolved hepatitis B virus infection is not a risk factor for the development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus or alcohol. Journal of Hepatology, 2017, 66, S455.	1.8	0
40	Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. European Journal of Gastroenterology and Hepatology, 2017, 29, 277-283.	0.8	33
41	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros. Medicina Clínica, 2017, 149, 61-71.	0.3	17
42	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. Gastroenterología Y Hepatología, 2017, 40, 515-524.	0.2	7
43	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Medicina Clínica (English Edition), 2017, 149, 61-71.	0.1	4
44	Adherence to a Semiannual Surveillance Program for Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology, 2017, 51, 557-563.	1.1	17
45	Bone metastases as initial presentation of hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1158-1165.	0.8	8
46	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology, 2016, 65, 719-726.	1.8	883
47	Analysis of the Frequency and Risk Factors Associated with Failure in Early Detection of Hepatocellular Carcinoma in a Surveillance Program in Patients with Cirrhosis. Journal of Hepatology, 2016, 64, S319.	1.8	0
48	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina Clínica (English Edition), 2016, 146, 511.e1-511.e22.	0.1	2
49	Prospective Analysis of Early Hospital Readmissions in Patients with Decompensated Cirrhosis and its Impact on Mortality. Journal of Hepatology, 2016, 64, S271.	1.8	0
50	Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events. Journal of Hepatology, 2016, 64, S319.	1.8	0
51	Diabetes is not Associated with an Increased Risk of Hepatocellular Carcinoma in Patients with Alcoholic, HBV or HCV Liver Cirrhosis. Journal of Hepatology, 2016, 64, S322.	1.8	0
52	Clinical Characteristics of Intrahepatic Cholangiocarcinoma in Spain. Liver Cirrhosis and High AFP are not Always Hepatocellular Carcinoma. Journal of Hepatology, 2016, 64, S322-S323.	1.8	0
53	P0145 : Prospective analysis of factors implicated in early readmissions in patients with decompensated cirrhosis. Journal of Hepatology, 2015, 62, S356.	1.8	0
54	New challenges in clinical research on hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2015, 108, 485-93.	0.1	12

#	ARTICLE	IF	CITATIONS
55	Occurrence of Hepatocellular Carcinoma upon Advanced Liver Fibrosis Thirteen Years After Achieving Sustained Virological Response to Hepatitis C: How Long Surveillance Should Be Maintained?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 582-585.	1.1	0
56	P0593 : Predictive model of HBsAg negativization in inactive HBsAg chronic carriers, mainly caucasian. <i>Journal of Hepatology</i> , 2015, 62, S538-S539.	1.8	0
57	P0125 : Hepatopulmonary syndrome (HPS) screening in patients with child A/B liver cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S347-S348.	1.8	0
58	P1072 CONCORDANCE BETWEEN INDICATIONS OF THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2014, 60, S434.	1.8	0
59	P570 ANALYSIS OF THE ADHERENCE TO A HEPATOCELLULAR CARCINOMA (HCC) SURVEILLANCE PROGRAMME BASED ON BIENNIAL CONTROLS. <i>Journal of Hepatology</i> , 2014, 60, S259.	1.8	2
60	Peritoneal carcinomatosis secondary to spread of hepatocellular carcinoma originated upon a healthy liver. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 53-54.	0.1	0
61	Annual Incidence of Hepatocellular Carcinoma Among Patients With Alcoholic Cirrhosis and Identification of Risk Groups. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 95-101.	2.4	129
62	274 TIME TO PROGRESSION TO AFP AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. <i>Journal of Hepatology</i> , 2013, 58, S116-S117.	1.8	0
63	557 ACUTE HEPATITIS E (HEV) IN A REGION OF NORTHERN SPAIN. <i>Journal of Hepatology</i> , 2012, 56, S221.	1.8	0
64	Personalized medicine in hepatocellular carcinoma: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 1403-1411.	0.0	1
65	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1239-1244.	0.8	18
66	Indolent evolution of an episode of acute gastroenteritis complicated with portal pneumatosis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 557-9.	0.1	4
67	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	2.0	403
68	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 97-104.	3.6	884
69	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007, 46, 474-481.	1.8	864
70	Reply: Chemoembolization with drug eluting beads in HCC. <i>Journal of Hepatology</i> , 2007, 47, 159.	1.8	1
71	[275] SEQUENCING OF HVRII AND HVRIII OF MITOCHONDRIAL DNA ALLOWS THE DISTINCTION BETWEEN DISSEMINATED AND SYNCHRONIC HEPATOCELLULAR CARCINOMA (HCC). <i>Journal of Hepatology</i> , 2007, 46, S110.	1.8	0
72	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S230-7.	1.8	14

#	ARTICLE	IF	CITATIONS
73	Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. <i>Journal of Hepatology</i> , 2006, 44, 8-10.	1.8	13
74	Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. <i>European Radiology</i> , 2006, 16, 2454-2462.	2.3	99
75	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1028-1036.	1.3	28
76	Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure. <i>Liver Transplantation</i> , 2006, 12, 1445-1447.	1.3	5
77	Staging systems in hepatocellular carcinoma. <i>Hpb</i> , 2005, 7, 35-41.	0.1	230
78	Ecografía con contraste de segunda generación (SonoVue®) en la valoración del tratamiento percutáneo del carcinoma hepatocelular. Comparación con la TC multifásica. <i>Radiología</i> , 2005, 47, 79-85.	0.3	1
79	Prognostic Prediction in Patients with Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 171-180.	1.8	80
80	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 1294-1300.	1.3	263
81	Selection of candidates with HCC for transplantation in the MELD era. <i>Liver Transplantation</i> , 2004, 10, S4-S9.	1.3	39
82	Ileal carcinoid tumor as a cause of massive lower-GI bleeding: the role of capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 483-485.	0.5	16
83	261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency. <i>Journal of Hepatology</i> , 2004, 40, 82.	1.8	0
84	273 Usefulness of sonovue microbubble-enhanced ultrasonography in the assessment of the efficacy of percutaneous ablation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 85.	1.8	1
85	Natural history and prognostic prediction of patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 98-102.	1.9	21
86	Hepatic failure due to primary AL amyloidosis. <i>Journal of Hepatology</i> , 2003, 39, 290.	1.8	10
87	Pseudotumoral hepatic tuberculosis. <i>Journal of Hepatology</i> , 2003, 39, 654.	1.8	12
88	Treatment of hepatocellular carcinoma: is there an optimal strategy?. <i>Cancer Treatment Reviews</i> , 2003, 29, 99-104.	3.4	61
89	Hepatoma. , 0, , 119-138.		0